|
gptkbp:instanceOf
|
biotechnology company
|
|
gptkbp:acquisition
|
gptkb:Crispr_Therapeutics
|
|
gptkbp:businessModel
|
partnerships
licensing agreements
therapeutics development
|
|
gptkbp:CEO
|
gptkb:John_Leonard
|
|
gptkbp:clinicalTrials
|
gptkb:NTLA-2001
gptkb:United_States
Europe
Phase 1
Phase 2
biopharmaceutical company
safety profile
promising outcomes
efficacy data
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:University_of_California,_Berkeley
gptkb:MIT
academic institutions
research organizations
|
|
gptkbp:focus
|
CRISPR gene editing
|
|
gptkbp:founded
|
2014
|
|
gptkbp:founder
|
gptkb:Jennifer_Doudna
|
|
gptkbp:funding
|
venture capital
|
|
gptkbp:future_plans
|
develop new therapies
expand pipeline
increase collaborations
|
|
gptkbp:headquarters
|
gptkb:Cambridge,_Massachusetts
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Intellia Therapeutics
|
|
gptkbp:investmentFocus
|
$100 million
|
|
gptkbp:leads
|
gptkb:NTLA-2001
gptkb:NTLA-2002
gptkb:NTLA-3001
NTLA-4001
NTLA-5001
|
|
gptkbp:market
|
genetic disorders
rare diseases
chronic diseases
|
|
gptkbp:partnerships
|
gptkb:Regeneron_Pharmaceuticals
Novartis
|
|
gptkbp:patentCitation
|
patents on CRISPR technology
patents on gene editing
patents on therapeutic applications
|
|
gptkbp:platforms
|
in vivo and ex vivo editing
|
|
gptkbp:regulatoryCompliance
|
gptkb:FDA
EMA
|
|
gptkbp:research_areas
|
oncology
autoimmune diseases
cardiovascular diseases
metabolic diseases
|
|
gptkbp:research_focus
|
genetic diseases
|
|
gptkbp:stockExchange
|
gptkb:NASDAQ
|
|
gptkbp:stockSymbol
|
NTLA
|
|
gptkbp:supportRole
|
experts in gene editing
|
|
gptkbp:technology
|
CRISPR/Cas9
|
|
gptkbp:tributaryOf
|
gptkb:NTLA-2002
|